William Hrushesky to Neoplasms
This is a "connection" page, showing publications William Hrushesky has written about Neoplasms.
Connection Strength
2.729
-
Reimagining Cancer: Moving from the Cellular to the Tissue Level. Cancer Res. 2023 01 18; 83(2):173-180.
Score: 0.378
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.248
-
Cancer as a changed tissue's way of life (when to treat, when to watch and when to think). Future Oncol. 2016 Mar; 12(5):647-57.
Score: 0.233
-
Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. Am J Manag Care. 2012 05 01; 18(5):e168-72.
Score: 0.180
-
Clock genes and cancer. Integr Cancer Ther. 2009 Dec; 8(4):303-8.
Score: 0.152
-
Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009 Dec; 8(4):387-97.
Score: 0.152
-
Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther. 2006 Aug; 5(8):2023-33.
Score: 0.121
-
Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther. 2003 Jun; 2(2):105-11.
Score: 0.097
-
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021 Aug; 8(8):e593-e604.
Score: 0.085
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
Score: 0.083
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.081
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.079
-
Circadian rhythms and cancer chemotherapy. Crit Rev Eukaryot Gene Expr. 1996; 6(4):299-343.
Score: 0.058
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.058
-
Larry Scheving and cancer chronotherapy. J Infus Chemother. 1995; 5(1):1-2.
Score: 0.054
-
Biological perspectives on circadian cancer therapy. J Infus Chemother. 1995; 5(4):182-90.
Score: 0.054
-
Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
Score: 0.054
-
The Department of Veterans Affairs' unique clinical cancer research effort. Cancer. 1994 Nov 01; 74(9 Suppl):2701-9.
Score: 0.053
-
Circadian cancer therapy. J Clin Oncol. 1993 Jul; 11(7):1403-17.
Score: 0.049
-
Circadian cancer pharmacodynamics. Ann Ist Super Sanita. 1993; 29(4):705-10.
Score: 0.047
-
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer. Ann N Y Acad Sci. 1991; 618:228-56.
Score: 0.041
-
More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story. Cancer Cells. 1990 Mar; 2(3):65-8.
Score: 0.039
-
Cancer chronotherapy: a drug delivery challenge. Prog Clin Biol Res. 1990; 341A:1-10.
Score: 0.038
-
In this issue: circadian disruption and cancer. Integr Cancer Ther. 2009 Dec; 8(4):295-7.
Score: 0.038
-
The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008 Nov; 19(11):1821-8.
Score: 0.034
-
Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol Int. 1986; 3(1):55-64.
Score: 0.029
-
Cancer chronomics III. Chronomics for cancer, aging, melatonin and experimental therapeutics researchers. J Exp Ther Oncol. 2006; 6(1):73-84.
Score: 0.029
-
Lack of antiemetic effect of high-dose metoclopramide. J Clin Oncol. 1985 Sep; 3(9):1273-6.
Score: 0.028
-
Circadian timing of cancer chemotherapy. Science. 1985 Apr 05; 228(4695):73-5.
Score: 0.028
-
Lack of age-dependent cisplatin nephrotoxicity. Am J Med. 1984 Apr; 76(4):579-84.
Score: 0.026
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
Score: 0.018
-
Erythropoietin usage in patients with cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):243-6.
Score: 0.014
-
Cancer chronotherapy: is there a right time in the day to treat? J Infus Chemother. 1995; 5(1):38-43.
Score: 0.014
-
Outpatient time-specified infusion of fluoropyrimidines by implanted pump is less costly than flat delivery by external pump. Prog Clin Biol Res. 1990; 341B:397-409.
Score: 0.010
-
The rationale for non-zero-order drug delivery using automatic, computer-based drug delivery systems (chronotherapy). J Biol Response Mod. 1987 Dec; 6(6):587-98.
Score: 0.008
-
Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans. Anticancer Res. 1986 Sep-Oct; 6(5):1137-44.
Score: 0.008
-
Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure. Chronobiol Int. 1984; 1(1):59-66.
Score: 0.006
-
Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther. 1982 Sep; 32(3):330-9.
Score: 0.006